Clinical Trial Update: 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

View source ↗

Summary

A clinical trial is evaluating the PET imaging tracer 18F-AlF-NOTA-Octreotide for neuroendocrine tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• [18F]AlF-NOTA-octreotide (18F-AlF-NOTA-octreotide)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Neuroendocrine Tumors | Status: NOT_YET_RECRUITING